Dr. Reddy’s Laboratories is currently trading at Rs. 2834.40, up by 8.00 points or 0.28% from its previous closing of Rs. 2826.40 on the BSE.
The scrip opened at Rs. 2800.00 and has touched a high and low of Rs. 2902.00 and Rs. 2800.00 respectively. So far 12898 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3363.00 on 20-Feb-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.
Last one week high and low of the scrip stood at Rs. 3083.00 and Rs. 2589.85 respectively. The current market cap of the company is Rs. 47791.92 crore.
The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.
Dr. Reddy's Laboratories has launched Ziprasidone Mesylate for Injection, 20 mg (base)/ml Single-dose Vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/ml, approved by the U.S. Food and Drug Administration (USFDA). According to IQVIA Health, the Geodon brand had U.S. sales of approximately $21.8 million MAT for the most recent twelve months ending in January 2020.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
